Public
Section
Experimental Biology 2003 - ASPET Program
Posters will
be presented daily from 12:30 pm - 2:45 pm in Hall B-E
Symposia
Saturday Morning
(9:30 am - 12:00 noon)
Inverse agonism: translation to in
vivo function
Chairs: James H. Woods and Richard Neubig
Current status of inverse agonism as a pharmacological and therapeutic
tool. Graeme Milligan, Univ. of Glasgow, Scotland
Delta-opioid inverse agonists. Chris J. Evans, UCLA
Inverse agonists in chemokine receptors. M.R. Brann,
Acadia Pharmaceut.
Inverse agonists and competitive antagonists in benzodiazepine
dependent monkeys. Charles P. France, Univ. of Texas
Hlth Sci. Ctr., San Antonio
Actions of hallucinogens and atypical antipsychotic
drugs at serotonin receptors
Chairs: Bryan L. Roth and David R. Sibley
Atomic and molecular mechanisms of 5-HT2A receptor activation,
targeting and trafficking. Bryan L. Roth, Case
Western Reserve Univ. Med. Sch.
RNA editing and genomic polymorphisms: relevance for schizophrenia,
atypical antipsychotics and
hallucinogens. Elaine Sanders-Bush,
Vanderbilt Univ. Med. Sch.
Functional roles of 5-HT2A receptors in the prefrontal cortex.
Rodrigo Andrade, Wayne State Univ. Med. Sch.
5-HT2A receptors in psychosis and antipsychotic treatments: insights
from knockout mice. Jay Gingrich,
Columbia Univ.
Serotonin 2C receptor distribution in the ventral tegmental area.
Marcy J. Bubar, Univ. of Texas Med. Br. at Galveston
(Abstract 3105)
A pharmacology core curriculum: to be or not to be
Chairs: Patricia B. Williams and Gregory D. Fink
Introduction: More than facts: knowledge, skills and attitudes.
Patricia B. Williams, Eastern Virginia Med. Sch.
The knowledge objectives and essential drug list. Gary Rosenfeld,
Univ. of Texas-Houston Med. Sch.
A view from the top: a chairman speaks. Kenneth E. Moore,
Michigan State Univ.
Teaching medical school pharmacology in the 21st century –
can a core knowledge base be defined? Eric P. Brass,
Harbor-UCLA Med. Ctr.
Beyond medical schools: health professions with
prescribing authority. Jean D. Deupree,
Univ. of Nebraska Med. Ctr.
Two pore-domain potassium channels: background
currents come to the fore
Chair: Steven J. Feinmark
The K2p channels: dedicated and
dynamic potassium leak pathways.. Steven A. Goldstein, Yale Univ.
Sch. of Med.
TREK and TASK channels: structure, regulation, pharmacology and
implications in disease states. Michel Lazdunski,
CNRS, Valbonne, France
Mechano- and lipid-sensitive two pore-domain postaaium channels in the
heart and brain. Donghee Kim, Finch
Univ. of Hlth. Sci.
Lipid-dependent modulation of TASK-1 function: is there a role in
dysregulation of cardiac rhythm? Richard Robinson,
Columbia Univ.
Functions of TASK channels in the mammalian central nervous system:
modulation by protons,
neurotransmitters and volatile
anesthetics. Douglas A. Bayliss,
Univ. of Virginia
Use of genomic data on drug metabolizing enzymes
and drug transporters to assess risk
Chairs: Richard T. Okita and Rebecca Blanchard
Building a pharmacogenetics database from scratch. Teri E. Klein,
Stanford Univ.
Cytochrome P450 protein models for predicting metabolic events
important in risk assessment, drug design and toxicology. Jeff
Jones, Washington State Univ.
Genetic regulation of ABC transporters. John Schuetz, St. Jude
Children's Research Med. Hosp.
Pharmacogenetics of human sulfotransferases. Rebecca
Blanchard, Fox Chase Cancer Ctr.
Identification and characterization of polymorphic variants of CYP3A5.
Su Jun Lee, NIEHS, Research Triangle Park, NC
(Abstract 9024)
Saturday Afternoon
(3:00 pm - 5:30 pm)
Cannabinoids: pharmacological actions and interactions between
endogenous brain cannabinoid and opioid systems
Chair: Steven R. Goldberg
Introduction. Recent progress in cannabinoid research. Steven R.
Goldberg, NIH, NIDA, Baltimore
Preclinical pharmacology of natural and synthetic
cannabinoids: tolerance, dependence and behavioral physiological
actions. B.R. Martin, Virginia Commonwealth Univ.
Endogenous cannabinoid systems and brain-behavior mechanisms.
Daniele Piomelli, UCI
Involvement of endogenous opioid systems in cannabinoid
dependence. Rafael Maldonado, Univ. of
Pompeu Fabra, Barcelona, Spain
Cannabinoid dependence in humans: role of endogenous
opioid systems. Margaret Haney, New
York State Psychiatric Inst. and Columbia Univ.
New developments in the search for natural and
synthetic cannabinoids. A. Makriyannis,
Univ. of Connecticut
Trophic effects of estrogen in the brain:
protection for memory, aging and neurodegenerative disease
Chairs: Cynthia M. Kuhn and Rochelle D. Schwartz-Bloom
Rapid signaling events mediate trophic actions of estrogen.
Dominique Toran-Allerand, Columbia Univ.
Estrogen and neuroinjury. Patricia Hurn, Johns
Hopkins Univ.
Estrogen is trophic for dopamine neurons: implications for Parkinson's
disease and addiction. Eugene Redmond, Yale Univ.
Estrogen and cognitive performance: basic and clinical findings.
Robert B. Gibbs, Univ. of Pittsburtgh Sch. of Med.
Teaching pharmacology to diverse audiences
Chairs: Jack W. Strandhoy and Patangi K. Rangachari
Introduction. Jack W. Strandhoy, Wake Forest Univ. Sch. of
Med.
PBL for undergraduate and graduate students: for the
few and the many. Patangi K. Rangachari,
McMaster Univ. Hlth. Sci. Ctr.
Designing facilities and programs to optimize education in the health
professions. O. Theodore Wendel, Arizona Sch. of Hlth. Sci.
Inquiry-based teaching of pathophysiology and pharmacology to 11th and
12th grade students. Jeffrey L. Osborn, Trinity Col. and
Academy
Tailoring problem based learning approaches to your audience. Ann
Lambros, Wake Forest Univ. Sch. of Med.
G -protein-coupled receptor kinases: hope or hype
for heart failure
Chair: Susan F. Steinberg
The structural basis of subtype specific signaling of beta
adrenoceptors in cardiac myocytes. Brian K. Kobilka,
Stanford Univ.
Mechanisms of GRK regulation. Jeffrey L. Benovic, Thomas
Jefferson Univ.
Distinct cardiomyocyte B1- and B2-adrenergic receptor signaling
phenotypes to cAMP and other effectors. Susan
F. Steinberg,
Columbia Univ.
New roles for GRK mediated beta-adrenergic receptor internalization in
heart failure. Howard Rockman,
Duke Univ. Med. Ctr.
Sunday Morning
(9:30 am - 12:00 noon)
Developing novel antidepressant drugs
Chair: Irwin Lucki
How antidepressants work: pathways to better drugs. Alan
Frazer, Univ. Texas Hlth. Sci. Ctr., San Antonio
Cellular and molecular targets for antidepressant drugs. Julie
Blendy, Univ. of Pennsylvania
PDE inhibitors as novel targets for antidepressants. James
O'Donnell, Univ. of Tennessee Hlth. Sci. Ctr.
Pharmacogenetic targets determining antidepressant drug effects.
Irwin Lucki, Univ. of Pennsylvania
Modeling anhedonia: reward deficits reversed by antidepressants.
Athina Markou, The Scripps Res. Inst.
Developmental neurotoxicology induced by NMDA antagonists/GABA
agonists
Chair: William Slikker
The importance of the NMDA receptor system to normal and abnormal
development. William Slikker,
NCTR/FDA, Jefferson, AR
Commonly used anesthesia protocol causes neuronal suicide in the
immature rat brain. Vesna Jevtovic-Todorovic,
Univ. of Virginia
Effect of chronic ethanol treatment on the expression of NR1 splice
variants in fetal cortical neurons. Meena Kumari,
Kansas State Univ.
Chronic exposure to sodium channel and NMDA receptor blockers during
development in rats and monkeys: long-term effects on cognitive
function. Merle G. Paule, NCTR, FDA, Jefferson, AR (Abstract
2714)
NMDA antagonists/GABA agonists exposure during development: unifying
mechanism of action, species
extrapolation and potential impact on children's
health. John Olney, Washington Univ.
Med. Sch.
Non-genomic effects of estrogen in
endothelial
cells
Chairs: Edward J. Kilbourne and James K. Liao
Estrogen receptor signaling through phosphatidylinositol-3-OH kinase.
James K. Liao, Harvard Med. Sch.
Estrogen stimulates endothelial eNOS through Hsp90
binding. Jeffrey R. Bender, Yale Univ.
Sch. of Med.
Estrogen preserves endothelial cell form and function.
Ellis R. Levin, Univ. of California at
Long Beach and Long Beach Vet. Affairs Med. Ctr.
Estrogen receptors and the cell SRFC (steroid receptor fast-action
complex). Philip W. Shaul, Univ. of Texas Southwestern Med. Ctr. at Dallas
Sex hormones and endothelin-TXA2 in Zucker diabetic rats. Adesuyi
L. Ajayi, Texas Southern Univ. (Abstract 583)
Monday Morning
(9:30 am - 12:00 noon)
Role of GABA-enhancing neurosteroids in
neuropharmacology
Chair: Richard W. Olsen
GABA-A receptor subunit specificity in the physiological modulation by
neurosteroids. Richard W. Olsen, UCLA
Neurosteroid effects on GABA-A receptor subunit plasticity: synaptic
and extrasynaptic actions. Sheryl Smith, SUNY at Brooklyn
Can the anxiolytic and antidysphoric profile of SSRIS be related to
their ability to increase neurosteroids active at GABA-A
receptors? Alessandro Guidotti, Univ.
of Illinois at Chicago
Endogenous GABAergic neurosteroids contribute to ethanol actions:
mechanisms and significance. Leslie Morrow,
Univ. of North Carolina at Chapel Hill
Trafficking of ion channels
Chair: Arthur M. Brown
Quality control in the ER: dislocation of integral
membrane proteins and their processing in the cytosol. Ron R. Kopito,
Stanford Univ.
Lipid rafts and membrane ion channels. Michael M. Tamkun,
Colorado State Univ.
Ion channel clustering. Peter G. Shrager,
Univ. of Rochester
HERG trafficking: pharmacological and physiological chaperones.
Eckhard Ficker, Case Western Reserve Univ.
Pharmacological management of
septicemia
Chair: J. Thomas Peterson
The biology of sepsis and appropriate preclinical
models. Fletcher B. Taylor,
Oklahoma Univ. Hlth. Sci. Ctr.
Anti-coagulant mechanisms in the treatment of sepsis.
Charles T. Esmon, Oklahoma Univ. Hlth.
Sci. Ctr.
Anti-inflammatory mechanisms in the treatment of
sepsis. Peter A. Ward, Univ. of
Michigan Med. Sch.
Establishing therapeutic efficacy and safety in the clinic - lessons
learned. Charles J. Fisher, Abbott Labs.
Regulation and physiological functions of extrahepatic cytosolic
sulfotransferases
Chair: Charles Falany
Structure and mechanism of sulfotransferases. Masahiko Negishi,
NIH, NIEHS,
Research Triangle Park, NC
Sulfation pharmacogenetics: genotype-to-phenotype studies. Richard
Weinshilboum,
Mayo Fndn.
Expression of human sulfotransferases in bacteria, cell lines and mice
for studying their role in the activation of mutagens
and carcinogens. Hansruedi Glatt,
German Inst. for Human Nutrition,
Bergolz-Rehbrucke, Germany
Steroid sulfation in human extrhepatic tissues.
Charles Falany, Univ. of Alabama at
Birmingham
Physiologic functions of estrogen sulfotransferase as revealed by gene
targeting in the
mouse. Wenchao Song, Univ. of Pennsylvania
Cyclooxygenase-2 and COX-2 inhibitors in
cardiovascular disease
Chairs: Leslie J. Crofford and Ben Lucchesi
The place of COXIBs in the treatment of rheumatic
diseases. Leslie J. Crofford, Univ. of
Michigan
COX-1 and COX-2-derived prostaglandins in vascular
biology. Tilo Grosser, Univ. of
Pennsylvania
Prostaglandins and hypertension: implications for use
of COXIBs. Tom Coffman, Duke Univ.
Does specific inhibition of COX-2 pose a cardiovascular
risk or benefit? Carlo Patrono, Univ.
of Rome
Tuesday Morning
(9:30 am - 12:00 noon)
Molecular substrates of anxiety: what have we
learned from GABAA receptor heterogeneity?
Chair: Phil Skolnick
Overview. Phil Skolnick, DOV Pharmaceut., Inc.
Molecular pharmacology of GABAA receptor
heterogeneity. Hartmut W.M. Lueddens,
Univ. of Mainz,
Germany
Analysis of GABAA receptor functions by knock-in point
mutations. Uwe Rudolph,
Univ. of Zurich, Switzerland
Subtype selective GABAA receptor ligands: can the in
vivo and in vitro pharmacologies be reconciled? Harry
June,
Indiana Univ. - Purdue Univ.
Searching for the "holy grail": can we develop
anxioselective drugs? Arnold S. Lippa,
DOV Pharmaceut., Inc.
Nicotinic receptors: connecting basic science to
therapeutic potential
Chairs: George J. Christ and Jerry J. Buccafusco
Honorary Chair: John P. Long
Crystal structure of AChBP. August B. Smit,
Vrije Univ., Amsterdam, The Netherlands
Phenotypes of nicotinic receptor knock out mice.
Lisa Marubio, Baylor Col. of Med.
Disease relevance: schizophrenia. Robert Freeman, Univ. of Colorado Hlth. Sci. Ctr.
The potential of nicotinic therapy for Alzheimer's
Disease and aging-related cognitive impairment. Edward D. Levin,
Duke Univ. Med. Ctr.
Nicotinic drugs improve learning and memory in
non-human primates. Jerry J. Buccafusco,
Med. Col. of Georgia
Transgenic models of heart failure and heart
failure therapeutics
Chairs: J. David Port and Joan Heller Brown
The role of HDACs in modulating cardiac hypertropy.
Timothy A. McKinsey, Myogen, Inc.,
Westminster, CO
Role of G-protein receptor kinases in modulating cardiac function and
rescue of heart failure phenotypes.
Walter J. Koch, Duke
Univ. Med. Ctr.
Role of G-proteins in the heart failure phenotype.
Gerald W. Dorn, Univ. of Cincinnati
Myocardial hypertrophy and failure induced by altered contractile
proteins. Leslie A. Leinwand, Univ. of Colorado
The PDZ binding motif of the beta2 adrenergic receptor modulates
receptor trafficking and signaling in cardiac myocytes. Yan Xiang,
Stanford Univ. (Abstract 8708)
Ophthalmic drug development: new frontiers or me
too?
Chair: Benjamin R. Yerxa
Ocular pharmacology, target diversity and drug development. Gary
Novack, PharmaLogic Development, INc., San Rafael, CA
Mechanisms in the pathogenesis of age related macular degeneration.
Marco Zarbin, UMDNJ
Preclinical studies in ophthalmology. Ward Peterson, Inspire
Pharmaceut., Inc.
Development of antisense therapies for CMV retinitis
and other ophthalmic diseases. Scott Henry,
Isis Pharmaceut., Inc.
Transcriptional suppression of cytochrome P450
genes by endogenous and exogenous chemicals
Chair: David S. Riddick
Positive and negative transcriptional regulation of cytochromes P450
by polycyclic aromatic hydrocarbons.
David S. Riddick,
Univ. of Toronto
Down-regulation of constitutive and inducible cytochromes P450 by
inflammatory mediators. Edward T. Morgan,
Emory Univ.
DHEA suppresses CYP2C11 expression through a PPAR-independent
mechanism. Russell A. Prough, Univ. of Louisville Sch. of
Med.
Bile acid and nuclear receptor regulation of cytochrome P450 gene
transcription. John Y.L. Chiang,
Northeastern Ohio Univ.
Suppression of the human sterol 12α hydroxylase (CYP8B1) gene by
interleukin-1ß (IL-1ß). Asmeen Jahan, Northeastern Ohio
Univ. Col. of Med. (Abstract 7285)
Tuesday Afternoon
(3:00 pm - 5:30 pm)
Animal models of neuropsychiatric diseases
Chairs: Frank I. Tarazi and Sabina Berretta
Mechanisms of behavioral hyperactivity in juvenile rats: implications
for ADHD. Frank I. Tarazi, Harvard Med. Sch.
Modeling Huntington's Disease in the mouse: mechanistic and
therapeutic insights. Susan Browne, Cornell Univ.
Role of subthalamic nucleus and substantia nigra pars reticulata in
primate parkinsonism. Thomas Wichmann, Emory Univ. Sch. of
Med.
Role of the amygdala in the pathophysiology of schizophrenia: a
"partial" rodent model. Sabina Berretta,
Harvard Med. Sch.
Isoform-specific regulation of adenylyl cyclases:
a new focus for drug discovery
Chairs: Ross D. Feldman and Paul A. Insel
Isoform-specific regulation of adenylyl cyclases by
GPCRs. Daniel R. Storm, Univ. of
Washington
Development of drugs targeted to specific adenylyl cyclase isoforms.
Yoshihiro Ishikawa, UMDNJ
Tyrosine kinase regulation of adenylyl cyclase isoforms.
Ross D. Feldman, John P. Robarts Res.
Inst., London, ON
Stoichiometry and compartmentation of signaling via adenylyl cyclases.
Paul A. Insel, UCSD
Vesicle monoamine transporters (VMATs)
Chair: Arnold E. Ruoho
Chemical neuroanatomy of the vesicular amine transporters: autonomous
and distributed aminergic phenotypes in the mammalian nervous system.
Lee E. Eiden, NIMH, NIH
The ligand binding sites and structure of VMAT2.
Arnold E. Ruoho,
Univ. of Wisconsin
Sch. of Med.
Mechanisms of coupling of H+ and substrate fluxes in
transporters: EmrE as a model
system. Shimon Schuldiner,
Hebrew Univ. of Jerusalem, Israel
Efflux mediated by VMAT2. Robert H. Edwards, UCSF
VMAT2 as a human gene for narcolepsy and dopaminergic disorders:
extended human VMAT2 haplotypes, imprinting and relationships to mouse
knockout models. George R. Uhl, NIDA, IRP,
NIH, Baltimore
Division
Sessions
Sunday Morning
(9:30 am - 12:00 noon)
Division for Pharmacology Education Session: Who controls and teaches
pharmacology in the new integrated curriculum?
Multiple learning formats provide opportunities and challenges to
teaching pharmacology. Jack W. Strandhoy, Wake Forest Univ.
Proposals for curriculum revision at Duke Medical School - their
impact on pharmacology education. J. Victor Nadler,
Duke Univ. Med. Sch.
Pharmacology in the medical school curriculum - experiences at Baylor
College of Medicine. Janet L. Stringer, Baylor Col. of
Med.
Division for Drug Metabolism Platform
Session: Biotransformation and drug transport
Chairs:
Michael R. Franklin and Thomas R. Kocarek
Sunday Afternoon
(3:00 pm - 5:30 pm)
Division for Toxicology Symposium: The dangers of
designer drugs
Chair: Terrence J. Monks
Selective neurotoxic effects of drugs of the amphetamine type.
George Ricaurte, Johns Hopkins Univ. Sch. of Med.
On the chemistry and heptaic metabolism of designer drugs of the
ecstasy and new piperazine type. Hans H. Maurer, Univ. of
Saarland, Homburg/Saar, Germany
MDMA metabolism in humans: pharmacodynamic and toxicological
implications. Rafael de la Torre, Inst. Municipal
D'Investigacio Medica, Barcelona, Spain
The neurotoxicity of metabolites of ecstasy. Terrence J. Monks,
Univ. of Texas at Austin
Division for Cardiovascular Pharmacology Best Paper
Award Presentations
Chairs: Mariana Morris and John Kermode
Graduate Student Presentations - 3:00 pm
Mechanisms of KATPopener-induced delayed cardioprotection.
E.R. Gross, Med. Col. of Wisconsin.
Glucocorticoids decrease GTP cyclohydrolase and tetrahydrobiopterin-dependent
vasodilation through glucocorticoid receptors. B.M. Mitchell,
Med. Col. of Georgia.
17ß-estradiol treatment suppresses IL-1ß-mediated induction of
cyclooxygenase-2 in rat cerebral blood vessels. J.A. Ospina,
Univ. of California, Irvine.
Postdoctoral Presentations - 4:00 pm
Stress-induced cardiovascular responses in oxytocin knockout (OTKO)
mice: is there an antistress effect of oxytocin? I. Bernatova,
Wright State Univ. Sch. of Med.
Diazoxide attenuates mitochondrial reactive oxygen species production
and calcium overload in cardiac myocytes following oxidant stress.
S. P. Jones, Johns Hopkins Univ.
Gene therapy of eNOS and MnSOD restores impaired wound healing in type
1 diabetes. J. -D. Luo, Michigan State Univ.
COX-2 is spatiotemporally implicated in HGF/SF-induced angiogenesis.
Possibility of chemoprevention by NSAIDs? S. Sengupta, MIT.
Business Meeting - 5:30 pm
Division for Clinical Pharmacology Symposium: Adrenergic signaling
pathways as a target for pharmacogenetic research
Chair: Terrence F. Blaschke
Genetic variants of adrenergic receptor signaling components: an
introductory overview.
Paul A. Insel, UCSD
Assessing the impact of alterations
in cellular adrenergic responses at a functional level: the
weakest link? Ross D. Feldman, John P. Robarts Res.
Inst., London, ON
In vivo
pharmacology of human adrenergic receptor polymorphisms. C. Michael
Stein, Vanderbilt Univ.
Alternative splicing
as a mechanisms for variation in drug response. Darrell R.
Abernethy, NIA, NIH, Baltimore, MD
Synergistic
polymorphisms on the ß1 and α2c-adrenergic
receptors and the risk of congestive heart failure. Kersten
Small, Univ. of Cincinnati Med. Ctr.
Division for Behavioral Pharmacology
Symposium: Learning and cognition: behavioral, pharmacological and
molecular relationships
Chair: James E. Barrett
Introduction.
James E. Barrett, Memory Pharmaceut.
Genetic approaches
to study learning and memory. Theodore G. Abel, Univ. of
Pennsylvania
Mechanisms of
learning in young and aging hippocampus. John F. Disterhoft,
Northwestern Univ. Med. Sch.
Calcium regulation
and gene expression in aging-related memory impairment. Philip W.
Landfield, Univ. of Kentucky
Drug Development for
cognitive enhancement. Gregory M. Rose, Memory Pharmaceut.
Monday Afternoon
(3:00 pm - 5:30 pm)
Division for Drug Discovery, Development and
Regulatory Affairs Symposium:
Clinical genomics: a source of pre-validated drug
targets and smart drugs
Chair: Benjamin R. Yerxa
Using multiple founder populations to discover new drug targets.
Michael R. Hayden, Univ. of British Columbia
The genealogic approach to finding human drug targets for human
disease. Jeffrey Gulcher, deCODE Genetics, Rejkjavik,
Iceland
Genetic profiling complex diseases for drug discovery and trials. Lindsay A. Farrer, Boston Medical Ctr.
Developing haplotypes for personalized medicine and smarter clinical.
trials. Clay Stephens, Genaissance Pharmaceut.,
Inc.
Division for Drug Metabolism Symposium:
Structural domains and motifs: functional
implications for drug-sensing transcription factors
Chair: Masahiko Negishi
Domain analysis of the Ah receptor. Lorenz Pollinger,
Karolinska Inst., Stockholm, Sweden
Multiple drug-binding orientations in the crystal structure of the
nuclear orphan receptor, PXR. Matthew R. Redinbo,
Univ. of North Carolina at Chapel Hill
Nrf2 and its protein-protein interactions regulate drug-dependent gene
induction. Masayuki Yamamoto, Univ. of Tsukuba, Tsukuba,
Japan
Mutational analysis of the nuclear orphan receptor CAR.
Masahiko Negishi, NIEHS, NIH, Research
Triangle Park
Division for Molecular Pharmacology Post Doctoral Award Finalists
Chair: Rick Neubig
Milliseconds to medicines: regulators of G-protein signaling (RGS) as
novel drug targets. Rick Neubig, Univ. of Michigan
Beta-arrestins regulate a Ra1GDS Ral effector pathway that mediates
cytoskeletal reorganization. Moshmi Bhattacharya, John P.
Robarts Res. Inst., London, ON (Abstract 9478)
Phosphorylation of AGS3 by tumor suppressor kinase LKB1: a potential
mechanisms for regulation of AGS3-Giα interaction. Joe B Blumer,
Louisiana State Univ. Hlth. Sci. Ctr. (Abstract 8083)
Prostaglandin E2 induction of early growth response
factor-1 by EP4 prostanoid receptors via
phosphatidylinositol 3-kinase and extracellular signal-regulated
kinases. Hiromichi Fujino, Univ. of Arizona Col. of Pharm.
(Abstract 4907)
Gq coupled receptor mediated ERK and Akt activation is attentuated by
expression of a peptide inhibitor of Gq in aorta vascular smooth
muscle cells. Jihee Kim, Duke Univ. Med. Ctr.
(Abstract 5889)
Ryanodine receptor phosphorylation and diastolic function are
increased by CAMKII in cardiomyocytes. Tong Zhang, UCSD
(Abstract 7565)
Division for Systems and Integrative Pharmacology
Symposium: Cocaine
neuropharmacology: integrating functional imaging and in vivo
neurochemistry
Chairs: Leonard L. Howell and Michael Nader
Use of PET imaging to characterize cocaine-induced changes in dopamine
D2 receptors in nonhuman primates. Michael A. Nader,
Wake Forest Univ. Med. Sch.
Effects of cocaine self-administration on dopaminergic
function determined by in vivo microdialysis in conscious
nonhuman primates. Charles W. Bradberry,
Yale Univ. Sch. of Med.
Monoamine transporters and cocaine medication
development in nonhuman primates: PET imaging and in vivo
microdialysis. Leonard L. Howell,
Emory Univ.
Cocaine-induced cerebral vasoconstriction determined by
fMRI in humans. Marc J. Kaufman,
McLean Hosp.
Neurochemical mechanisms mediating cue-induced cocaine
craving in humans determined by PET imaging and fMRI. Anna Rose
Childress, Univ. of Pennsylvania
Division for Neuropharmacology Symposium: Club
drugs – neuropharmacology: new challenges
Chair: Jerry Frankenheim
The "club drugs" present new challenges. Jerry Frankenheim,
NIDA, NIH
Neurotoxic amphetamines. Bryan K. Yamamoto, Boston Univ.
Functional consequences of MDMA abuse. John E. Mendelson,
UCSF
GHB physiology and pharmacology. O. Carter Snead III, Univ.
of Toronto
Hallucinogens: from LSD to mescaline. Gerard J. Marek,
Pfizer, Inc.
Neurotoxicity of NMDA antagonists (ketamine, PCP, N20, ethanol) in the
adult and developing brain. John W. Olney, Washington Univ.
Special Sessions
Friday Afternoon
(2:00 pm - 6:00 pm)
Teaching Institute:
Challenges in pharmacology graduate education
2:30 pm - 4:00 pm
A classical approach to teaching pharmacology to graduate students.
Barbara S. Beckman, Tulane Univ.
A core curriculum for graduate studies at MUSC. Perry V. Halushka,
Med. Univ. of South Carolina
Experience with a core curriculum for graduate students at LSU/Shreveport:
pros and cons. Sandra Roerig, Louisiana State Univ. at
Shreveport
Graduate student panel:
Lawrence P. Carter, Univ. of Texas Hlth. Sci. Ctr. at
San Antonio, Ted Price, Univ. of Texas Hlth. Sci. Ctr.
at San Antonio, Laila Elsherif, Univ. of
Louisville
Graduate Student Colloquium: Practical tips for success in
pharmacology graduate program and beyond
4:30 pm - 6:00 pm
The importance of networking: establishing ifelines for long-term
survival. Richard De La Garza, Albert
Einstein Col. of Med.
Information overload: swimming rather than sinking in the sea of
knowledge. David B. Bylund,
Univ. of Nebraska Med. Ctr.
Saturday Morning
(8:30 am - 11:00 am)
Workshop: Securing
your future through competitive grant writing
(Sponsored by the Committee on Minorities)
Moderator: Sunny E. Ohia
Goal: To provide an opportunity for the panelists to discuss their
experiences in securing funding from governmental and non-governmental
sources based on winning grant proposals.
Funding opportunities at the predoctoral level.
Ashiwel S. Undie, Univ. of Maryland Sch.
of Pharmacy
Funding opportunities at the postdoctoral level.
Richard De La Garza, II, Albert Einstein
Col. of Med.
Funding opportunities at the faculty level. Rita J. Valentino,
Children’s Hosp. of
Philadelphia
Sunday Afternoon
(3:00 pm - 5:30 pm)
Symposium: Drug abuse as a gender issue
(Sponsored by the Women in Pharmacology Committee)
Chairs: Linda P. Dwoskin and Kathleen M. Kantak
Response to alcohol and alprazolam in women with potential risk
factors for developing substance abuse
problems. Suzette M. Evans,
Columbia Univ. Col. of P and S
Sex differences in the anxiety-reducing effects of
abused drugs. Marlene A. Wilson, Univ.
of South Carolina Sch. of Med.
Gender differences in substance use disorders.
Kathleen Brady, Med. Univ. of South
Carolina
Sex differences in the acquisition, maintenance, reinstatement, and
treatment of drug abuse: animal models.
Marilyn E. Carroll,
Univ. of Minnesota
Hormonal effects on withdrawal and smoking behavior with and without
transdermal nicotine in pre- and post-menopausal women
during short-term smoking cessation. Sharon Allen,
Univ. of Minnesota
Sex differences and nicotine reinforcement in animals
and humans. Nadia Chaudhri, Univ. of
Pittsburgh
Monday Morning
(8:00 am - 10:00 am)
Workshop:
Presentation Skills
(Sponsored by ASPET’s Women in Pharmacology Committee and APS’ Women
in Physiology Committee)
Chairs: Carole M. Liedtke, Siribhinya Benhyajati, and Joan Lakoski
Introduction. Carole M. Liedtke, Case Western Reserve Univ.
Oral presentations. Kim Barrett, UCSD
Interviewing skills. Ann M. Schreihofer, Med. Col. of
Georgia
Poster presentations. Joan M. Lakoski, Univ. of Pittsburgh
Sharing science with the public/media. Mary J. Hendrix, Univ.
of Iowa
Wrap up. Sinya Benyajati, Univ. of Oklahoma Hlth. Sci.
Ctr.
Monday Morning (9:45 - 12:00)
Recruiting, Educating and Mentoring the Experimental Biologists of
the Future
(Sponsored by AAA, APS, ASBMB, ASIP, ASNS, ASPET)
Facilitator: Gregory Milman, NIAID
Participants: Margaret Bentley (ASNS), Frank Belloni
(APS), Gary Rosenfeld (ASPET), Robert Bowser (ASIP), Richard Marchase
(AAA), A. Stephen DAhms, (ASBMB)
Due to the phenomenal changing dynamics of the biomedical and related
life sciences and their interdisciplinary interplay, professional
societies and institutions at all levels are experiencing
unprecedented demands in developing and maintaining the production of
experimental biologists who are adequately prepared to deal with the
current new scientific and technological environments, let alone those
of the future. The source of future experimental biologists, the
changing educational strategies deployed in their education , and the
mechanisms of their mentoring are all open to question and susceptible
to change. This session addresses both the common concerns of
the six participating societies at EB 2003, as well as the
society-specific concerns. Aspects of core curricula and
problems associated with creation of integrated curricula,
differentiation in the training of biomedical scientists, new paths in
problem-based learning, new tactics in mentoring, assurance of
diversity, challenges of "alternate career" preparation,
entrepreneurial training, and the preparation of life scientists for
industrial biology, as well as other topics will be discussed by
society representatives in both formal presentations and a panel
session.
Lectures
The Torald Sollmann Award in Pharmacology Oration
The Changing Face of Pharmacology: A True Chimera or in Transition
Palmer W. Taylor, UCSD
Saturday 1:45 pm - 2:45 pm
The Harry Gold Award in Clinical Pharmacology Lecture
Conjugation Pharmacogenetics: Phenotype to Genotype and Back
Richard M. Weinshilboum, Mayo Fndn.
Sunday, 1:45 pm - 2:45 pm
|
